Huntington's disease: Advocacy driving science

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 1-22

  Wexler, Nancy S ^a,b  

^a Columbia University ^*  (United States)

^b Hereditary Disease Foundation   (United States)

Author keywords

Gene Hunters; Hereditary Disease Foundation; Human genetics; Huntingtin; Kindreds; Venezuela

Indexed keywords

ALPHA TOCOPHEROL; BACLOFEN; CREATINE; HALOPERIDOL; HUNTINGTIN; IDEBENONE; LAMOTRIGINE; MINOCYCLINE; POLYGLUTAMINE; REMACEMIDE; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; UBIQUINONE;

ANXIETY DISORDER; AUTOPHAGOSOME; AUTOSOMAL DOMINANT INHERITANCE; BRADYKINESIA; CAG REPEAT; CHROMOSOMAL LOCALIZATION; DEPRESSION; DNA MARKER; DNA SEQUENCE; DYSPHAGIA; DYSTONIA; FAMILY HISTORY; FAMILY STRESS; GASTROSTOMY; GENE IDENTIFICATION; GENE ISOLATION; GENE LOCATION; GENE LOCUS; GENE SILENCING; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; NERVE FIBER; NEURITE; NEUROPROTECTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; TARDIVE DYSKINESIA; VENEZUELA; WEIGHT REDUCTION;

ANIMALS; FEMALE; FOUNDATIONS; GENETICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUNTINGTON DISEASE; NEUROSCIENCES; PATIENT ADVOCACY; UNITED STATES; VENEZUELA;

EID: 84855973422     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050710-134457     Document Type: Review

References (54)

1. Wexler M. 2002. Hereditary Disease Foundation. In A Look Through the Rearview Mirror, pp. 331-37. Bloomington, IN: Xlibris Corp. 343 pp.
2. Wexler A. 1996. Mapping Fate: A Memoir of Family, Risk, and Genetic Research, pp. 105, 173, 177. Berkeley and Los Angeles: Univ. Calif. Press. 321 pp.
3. Hereditary Disease Foundation. http://www.hdfoundation.org
4. Botstein D, White RL, Skolnick M, et al. 1980. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet. 32(3):314-31 (Pubitemid 11105557)
5. Brown MS, Dana SE, Goldstein JL. 1974. Regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity in cultured human fibroblasts.Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 249(3):789-96
6. 1973. Centennial Symposium on Huntington's Chorea. Adv. Neurol. 1:4-5
7. Negrette A. 1955. Corea de Huntington: Estudio de Una Sola Familia a Traves de Varias Genereaciones. Maracaibo, Venezuela: Univ. Zulia, Maracaibo
8. Huntington Study Group. 1996. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 11(2):136-42
9. Young AB, Shoulson I, Penney JB, et al. 1986. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36:244-49 (Pubitemid 16124216)
10. Penney JB, Young AB, Shoulson I, et al. 1990. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord. 5:2:93-99 (Pubitemid 20166182)
11. Gusella JF, Wexler NS, Conneally PM, et al. 1983. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306(5940):234-38 (Pubitemid 14232350)
12. Watson JD, Berry A. 2003. DNA: The Secret of Life, p. 303. New York: Alfred A. Knopf
13. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-83
14. Angier N. 1993. Researchers locate gene that triggers Huntington's illness. New York Times, Mar. 24, p. A1
15. The US-Venezuela Collaborative Research Project and Wexler NS. 2004. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. USA 101(15):3498-503
16. Wexler NS, Young AB, Tanzi RE, et al. 1987. Homozygotes forHuntington's disease. Nature 326:194-97
17. Duyao MP, Ambrose CM, Myers RH, et al. 1993. Trinucleotide repeat length: instability and age of onset in Huntington's disease. Nat. Genet. 4:387-92
18. Leeflang EP, Zhang L, Tavaŕe S, et al. 1995. Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Hum. Mol. Genet. 4(9):1519-26
19. Andresen JM, Gaýan J, Cherny SS, et al. 2006. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J. Med. Genet. 44:44-50 (Pubitemid 46142838)
20. Andresen JM, Gaýan J, Djousśe L, et al. 2006. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann. Hum. Gen. 71:295-301
21. Gaýan J, Brocklebank D, Andresen JM, et al. 2008. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet. Epidemiol. 32(5):445-53
22. Brocklebank D, Gaýan J, Andresen JM, et al. 2009. Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. Am. J. Med. Genet. B Neuropsychiatr Genet. 150B(3):425-29
23. Li J-L, Hayden MR, Almqvis EW, et al. 2003. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS Study. Am. J. Hum. Genet. 73:682-87 (Pubitemid 37076283)
24. Mangiarini L, Sathasivam K, Seller M, et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493-506 (Pubitemid 26374323)
25. Davies SW, Turmaine M, Cozens BA, et al. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-48 (Pubitemid 27347243)
26. Yamamoto A, Lucas JJ, Hen R. 2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101(1):57-66
27. Southwell AL, Ko J, Patterson PH. 2009. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 29(43):13589-602
28. Snyder-Keller A, McLear JA, Hathorn T, et al. 2010. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6. HDR6/1 mice. J. Neuropathol. Exp. Neurol. 69(10):1078-85
29. Tam S, Spiess C, Auyeung W, et al. 2009. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat. Struct. Mol. Biol. 16(12):1279-85
30. Thompson LM, Aiken CT, Kaltenbach LS, et al. 2009. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187(7):1083-99
31. Gray M, Shirasaki DI, Cepeda C, et al. 2008. Full length human mutant Huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28:6182-95
32. Gu X, Greiner ER, Mishra R, et al. 2009. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64(6):828-40
33. Harper SQ, Staber PD, He X, et al. 2005. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102(16):5820-25 (Pubitemid 40559643)
34. Pfister EL, Kennington L, Straubhaar J, et al. 2009. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 19(9):774-78
35. Gu X, Li C, Wei W, et al. 2005. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46(3):433-44 (Pubitemid 40616887)
36. Gu X, Andŕe VM, Cepeda C, et al. 2007. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2:8
37. Shoulson I, Odoroff C, Oakes D, et al. 1989. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol. 25(3):252-59 (Pubitemid 19085516)
38. Peyser CE, Folstein M, Chase GA, et al. 1995. Trial of d-alpha-tocopherol in Huntington's disease. Am. J. Psychiatry 152(12):1771-75
39. Ranen NG, Peyser CE, Coyle JT, et al. 1996. A controlled trial of idebenone in Huntington's disease. Mov. Disord. 11(5):549-54 (Pubitemid 26306081)
40. Kremer B, Clark CM, Almqvist EW, et al. 1999. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53(5):1000-11 (Pubitemid 29442116)
41. Huntington Study Group. 2001. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57(3):397-404
42. Verbessem P, Lemiere J, Eijnde BO, et al. 2003. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61(7):925-30 (Pubitemid 37248646)
43. Puri BK, Leavitt BR, Hayden MR, et al. 2005. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65(2):286-92 (Pubitemid 41022376)
44. Landwehrmeyer GB, Dubois B, de Ýebenes JG, et al. 2007. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62(3):262-72 (Pubitemid 47525402)
45. Huntington Study Group DOMINO Investigators. 2010. A futility study of minocycline inHuntington's disease. Mov. Disord. 25(13):2219-24
46. Hersch SM, Gevorkian S, Marder K, et al. 2006. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'd G. Neurology 66(2):250-52 (Pubitemid 43970166)
47. Huntington Study Group. 2006. Tetrabenazine as antichorea therapy inHuntington disease: a randomized controlled trial. Neurology 66(3):366-72
48. Mindham RH, Steele C, Folstein MF, et al. 1985. A comparison of the frequency of major affective disorder in Huntington's disease and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 48(11):1172-74 (Pubitemid 16248156)
49. Paulson JS, Hoth KF, Nehl C, et al. 2005. Critical periods of suicide risk in Huntington's disease. Am. J. Psychiatry 162(4):725-31 (Pubitemid 40489135)
50. Wexler A. 2008. The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease, pp. 126, 134, 160-61, 169. New Haven/London: Yale Univ. Press. 280 pp.
51. Wexler AR. 2010. Stigma, history, and Huntington's disease. Lancet 376(9734):18-19
52. Kevles DJ. 1985. In the Name of Eugenics: Genetics and the Uses of Human Heredity. New York: Alfred A. Knopf. 426 pp.
53. Davenport CB, Muncey EB. 1916. Huntington's chorea in relation to heredity and eugenics. Am. J. Psychiatry 2:195
54. Critchley M. 1934. Huntington's chorea and East Anglia. J. State Med. 42:575-87